MAXIND · NSE
Max India Limited
₹152.69
+8.92% (+₹12.5)
Prev. close
₹140.19
Volume
2,16,930
Delivery %
55.6%
As of
18 Sept 2026
Price history
No analyst calls on this stock in the last 90 days yet.
Explore by date range →Analyst opinions
Fundamentals
About Max India Limited
Max India Limited provides services related to senior living communities in India. It operates through four segments: Business Investments, Senior Living, Assisted Care, and Others. The company engages in treasury investments and property rental businesses. It also constructs, operates, and/or maintains senior living communities. In addition, the company caters to the seniors by providing care at home services and care homes facilities, as well as offers Antara AGEasy, a new-age holistic direct to consumer platform that helps seniors manage common chronic conditions. Further, it offers daily living/specialized care/memory care services for seniors; and management and consultancy and shared services. Additionally, the company engages in the learning and development activities; leasing of senior living communities; and management of investments activities. The company was formerly known as Advaita Allied Health Services Limited. Max India Limited was incorporated in 2019 and is based in Gurugram, India.
Details
Sector
Healthcare
Industry
Medical Care Facilities
CEO
Mr. Ishaan Khanna
Headquarters
Gurugram
Employees
19
Website
maxindia.comExchange
View on NSE ↗Key stats
Market cap
₹859.96 Cr
EPS (TTM)
₹-25.32
Beta (1Y · daily vs NIFTY 50)
1.31
Beta (5Y · monthly vs NIFTY 50)
1.38
Shares float
2.60 Cr
EPS · quarter ended Jun 2026
₹-6.91
Financial Performance
01 · Financials
Revenue for Mar 2022–Mar 2022 is as filed with BSE (consolidated), and the first plotted growth figure is computed against Mar 2021 revenue as filed with BSE; the two sources' revenue definitions differ by 0.0% on Mar 2023. FY22 growth needs FY21 filings, which the data source doesn't provide. EBITDA is omitted from this chart: coverage begins inside the plotted window, and every plotted period must carry a complete point set — the P&L table below has the available figures.
02 · Earnings Per Share (EPS)
04 · Operating Efficiency (Growth Rates)
Balance-sheet-based
05 · Capital Structure & Asset Utilization
Asset turnover needs a prior year of assets — omitted for the earliest available year.
06 · Asset Base Composition
07 · Debt Level & Coverage
08 · Profit & Loss
Annual
| Line item | FY21 | FY22 | FY23 | FY24 | FY25 | FY26 |
|---|---|---|---|---|---|---|
| ₹120.88 Cr | ₹229.88 Cr | ₹201.03 Cr | ₹175.63 Cr | ₹145.49 Cr | ₹190.56 Cr | |
| EBITDA | — | — | ₹11.65 Cr | ₹-34.32 Cr | ₹-111.50 Cr | ₹-82.08 Cr |
| ₹-53.10 Cr | ₹-18.04 Cr | ₹-10.38 Cr | ₹-56.38 Cr | ₹-140.39 Cr | ₹-121.85 Cr | |
| Diluted EPS | ₹-9.88 | ₹-3.35 | ₹-2.06 | ₹-12.36 | ₹-31.55 | ₹-23.85 |
Depreciation & amortisation, EBITDA, Pretax income, Tax provision, Interest expense have filed figures for only some of the years shown — the missing years are left blank rather than estimated.
09 · Balance Sheet
Annual
| Line item | FY21 | FY22 | FY23 | FY24 | FY25 | FY26 |
|---|---|---|---|---|---|---|
| ₹997.61 Cr | ₹858.32 Cr | ₹753.40 Cr | ₹684.34 Cr | ₹632.85 Cr | ₹669.25 Cr | |
| ₹112.35 Cr | ₹60.76 Cr | ₹45.30 Cr | ₹43.57 Cr | ₹102.30 Cr | ₹96.20 Cr | |
| Stockholders' equity | — | — | ₹542.11 Cr | ₹492.34 Cr | ₹358.69 Cr | ₹408.30 Cr |
Current assets, Cash & equivalents, Non-current assets, Fixed assets, Long-term debt, Current (short-term) debt, Others, Stockholders' equity have filed figures for only some of the years shown — the missing years are left blank rather than estimated. CWIP has no filed figures within the years shown — left blank rather than estimated.
Annual only — the data source doesn’t publish quarterly balance-sheet detail for most NSE-listed companies.
10 · Cash Flow Statement
Annual
| Line item | FY21 | FY22 | FY23 | FY24 | FY25 | FY26 |
|---|---|---|---|---|---|---|
| ₹72.67 Cr | ₹66.50 Cr | ₹69.42 Cr | ₹-102.34 Cr | ₹-127.60 Cr | ₹-94.72 Cr | |
| Investing cash flow | ₹12.51 Cr | ₹32.25 Cr | ₹124.07 Cr | ₹158.64 Cr | ₹46.82 Cr | ₹-49.72 Cr |
| ₹-73.30 Cr | ₹-93.94 Cr | ₹-118.54 Cr | ₹-29.00 Cr | ₹-12.55 Cr | ₹148.32 Cr | |
| Capital expenditure | ₹-11.75 Cr | ₹-6.70 Cr | ₹-3.66 Cr | ₹-28.75 Cr | ₹-35.88 Cr | ₹-51.33 Cr |
| End cash position | — | — | ₹88.73 Cr | ₹116.03 Cr | ₹22.70 Cr | ₹26.58 Cr |
Depreciation & amortization, Change in working capital, Debt issued, Debt repaid, End cash position have filed figures for only some of the years shown — the missing years are left blank rather than estimated.
Annual only — the data source has no quarterly cash-flow-statement coverage.
11 · Shareholding Pattern
NSE, quarterly
| Line item | Sep 21–Jun 22(4Q) | Aug 22–Jun 23(5Q) | Sep 23–Dec 24(6Q) | Mar 25–May 25(2Q) | Jun 25 | Sep 25 | Dec 25 | Mar 26 | Jun 26 | Jul 26 |
|---|---|---|---|---|---|---|---|---|---|---|
| Promoter | 40.89% | 51.11% | 50.94% | 50.45% | 50.16% | 50.05% | 49.89% | 49.82% | 49.77% | 48.33% |
| Public | 59.11% | 48.89% | 49.06% | 49.55% | 49.84% | 49.95% | 50.11% | 50.18% | 50.23% | 51.67% |
| Employee trusts | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
Source: NSE quarterly shareholding-pattern filings, collapsed to periods where the reported percentages held steady — a column spanning several quarters means no change was filed across them. No FII/DII sub-split available from this source — Public includes all non-promoter, non-employee-trust holders.
12 · Peer Comparison
Healthcare
| Company | ||||||||
|---|---|---|---|---|---|---|---|---|
| Sun Pharmaceutical Industries Limited | ₹4.48 L Cr | ₹1,837.3 | 37.0 | 5.36 | 13.7% | 0.06 | +11.9% | +11.4% |
| Divi's Laboratories Limited | ₹2.47 L Cr | ₹9,375 | 83.3 | 14.77 | 15.3% | 0.00 | +12.3% | +53.4% |
| Torrent Pharmaceuticals Limited | ₹1.83 L Cr | ₹4,875 | 76.9 | 21.82 | 25.8% | 1.79 | +21.5% | +37.4% |
| Apollo Hospitals Enterprise Limited | ₹1.26 L Cr | ₹8,944.5 | 60.4 | 13.30 | 20.5% | 0.90 | +15.7% | +13.9% |
| Lenskart Solutions Limited | ₹1.18 L Cr | ₹707.2 | 179.9 | 13.48 | 5.6% | 0.35 | +35.4% | — |
| Zydus Lifesciences Limited | ₹1.13 L Cr | ₹1,160 | 25.3 | 4.18 | 18.6% | 0.46 | +18.4% | +10.7% |
| Cipla Limited | ₹1.10 L Cr | ₹1,376.3 | 32.5 | 3.19 | 11.3% | 0.02 | +2.1% | -11.8% |
| Laurus Labs Limited | ₹1.05 L Cr | ₹1,954 | 96.4 | 19.86 | 16.8% | 0.48 | +22.0% | +111.6% |
| Max Healthcare Institute Limited | ₹1.01 L Cr | ₹1,049.3 | 69.8 | 9.39 | 13.4% | 0.32 | +19.0% | -10.6% |
| Dr. Reddy's Laboratories Limited | ₹97,876.16 Cr | ₹1,185 | 29.6 | 2.60 | 11.4% | 0.21 | +3.2% | -10.4% |
| Manipal Health Enterprises Limited | ₹97,364.22 Cr | ₹738.95 | 146.6 | 11.56 | 7.8% | 1.53 | +18.0% | — |
| Max India Limited | ₹786.46 Cr | ₹140.19 | — | 1.93 | -29.8% | 0.24 | +31.0% | -34.3% |
Ranked by market cap within Healthcare, same metrics as the Fundamentals screener. Click a column to sort.
Documents
Annual reports
Concall transcripts
Show all 12
Official documents linked from their sources — offer documents as filed with SEBI (sebi.gov.in), annual reports and earnings-call transcripts as published on BSE (bseindia.com) and NSE (nseindia.com). Links open the source's own hosting; nothing is re-hosted here.
Index membership
1 index
Weight is BSE’s own published index weight. Indices without weight data are listed without one, in alphabetical order after the weighted ones.